Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.62 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | BLVRB | P30043 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427656 | 1.00 | S1PR1 (0.62) | S1PR1S1PR5FFAR4S1PR4MAOA | |
| SCHEMBL3740660 | 1.00 | S1PR1 (0.62) | S1PR1S1PR5FFAR4S1PR4MAOA | |
| SCHEMBL3739690 | 0.86 | S1PR1 (0.69) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3429036 | 0.86 | S1PR1 (0.69) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3740478 | 0.86 | S1PR1 (0.69) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3747202 | 0.79 | S1PR1 (0.64) | S1PR1S1PR5FFAR4S1PR4 | |
| SCHEMBL3426490 | 0.79 | S1PR1 (0.64) | S1PR1S1PR5FFAR4S1PR4 | |
| SCHEMBL3746538 | 0.79 | S1PR1 (0.64) | S1PR1S1PR5FFAR4S1PR4 | |
| SCHEMBL3427845 | 0.78 | S1PR1 (0.67) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3750795 | 0.78 | S1PR1 (0.67) | S1PR1S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR5 4/4885FFAR4 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.